AI assistant
Elicio Therapeutics, Inc. — Director's Dealing 2021
Feb 4, 2021
33784_dirs_2021-02-04_0a34f11a-ec98-42d1-a749-b13c5d5b9fd7.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Angion Biomedica Corp. (ANG)
CIK: 0001601485
Period of Report: 2021-02-04
Reporting Person: GANZI VICTOR F (Director)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 386664 | Direct |
| Common Stock | 155581 | Indirect |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $9.52 | 2030-02-13 | Common Stock (38895) | Direct | |
| Convertible Promissory Note | $11.57 | Common Stock (18718) | Direct | ||
| Convertible Promissory Note | $11.57 | Common Stock (50060) | Direct | ||
| Warrant to Purchase Common Stock | $6.42 | 2028-07-05 | Common Stock (351101) | Direct | |
| Warrant to Purchase Common Stock | $8.03 | 2023-08-31 | Common Stock (92888) | Direct |
Footnotes
F1: Reflects a 1-to-1.55583 stock split of the Issuer's outstanding securities effected prior to the effectiveness of the Issuer's S-1 Registration Statement.
F2: Victor F. Ganzi 2012 GST Family Trust.
F3: One thirty-six (1/36th) of the shares subject to the option will vest on each monthly anniversary measured from April 1, 2020 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the third anniversary of the Vesting Commencement Date.
F4: The convertible promissory note has a maturity date of May 28, 2021, and the principal and accrued interest will convert immediately prior to the consummation of the IPO into Common Stock at a conversion price equal to $11.57 per share.
F5: The convertible promissory note has a maturity date of August 21, 2021, and the principal and accrued interest will convert immediately prior to the consummation of the IPO into Common Stock at a conversion price equal to $11.57 per share.
F6: The warrants to acquire Common Stock shall automatically net exercise immediately prior to the consummation of the IPO at the public offering price.
F7: The warrant has a net exercise provision under which the holder, in lieu of paying the exercise price in cash, can surrender the warrant and receive a net number of shares of common stock based on the fair market value of such stock at the time of exercise, after deducting the aggregate exercise price.